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Study design: This study is a retrospective review of Cochrane CENTRAL database, MEDLINE, and Embase through June 15, 2018.
Key findings: Analysis of 22 studies involving 80,428 patients with abdominal aortic aneurysms (AAAs) revealed that statin use is associated with a mean AAA growth rate reduction of 0.82 mm/y (P ¼ .001), lower rupture risk (P < .0001), and lower 30-day mortality after elective AAA repair (P ¼ .005). The crude rupture rate was 34% for statin patients and 47% for control patients. The crude 30-day mortality rate was 1.8% for the statin group and 2.6% for the control group. The largest effect was in patients who underwent open AAA repair as opposed to endovascular aneurysm repair.
Conclusion: Statin use may be associated with reduction in AAA growth, rupture, and perioperative mortality after elective AAA repair.
Commentary: Statins reduce vascular inflammation and can play a key role in the collagenolytic pathway involved in AAA progression. Statins reduce collagen breakdown by stabilizing matrix metalloproteinases and reduce intramural aortic matrix metalloproteinase expression. Overexpression of these collagenases is thought to cause AAA development and progression. The authors' findings did not allow them to suggest specific statins, doses, or minimum duration of therapy required to achieve the suggested benefits of AAA outcome. The study showed that AAAs grow about 1 mm slower per year if a patient takes statins (more slowly for larger aneurysms). I agree with the authors that "current evidence suggests that many vascular surgery patients are not adequately risk factor controlled" and "a substantial missed opportunity may exist for the reduction of mortality following both open and EVAR repair of AAA." Patients with AAAs being observed with serial surveillance studies or being considered for surgery should be taking statins, and we need to have protocols to ensure that they are.
Carotid stenting in patients before cardiac surgery Key findings: There were 643 patients with 80% to 99% carotid artery stenosis (one-quarter with history of stroke) who underwent carotid artery stenting (CAS) approximately 1 month before planned coronary artery bypass, cardiac valve surgery, or aortic arch surgery. Clopidogrel (Plavix) was stopped 5 days before heart surgery. The composite outcome of death, stroke, and myocardial infarction (MI) was 26% at 5 years and 47% at 8 years. Independent risk factors for the composite outcome during follow-up included age $80 years, history of stroke, chronic obstructive pulmonary disease, and kidney disease.
Conclusion: In this study of CAS followed by cardiac surgery about 1 month later, octogenarians and patients with history of stroke or severe pulmonary or renal disease had higher long-term rates of death, stroke, and MI.
Commentary: There are very few large series of patients or any randomized clinical trials examining the benefits of CAS before heart surgery. I do not think any of us are surprised that age >80 years and history of stroke, chronic obstructive pulmonary disease, or kidney disease were identified as risk factors for death, stroke, or MI after staged CAS and heart surgery.
I am not sure what to conclude from these results. The authors do not offer any helpful recommendations about when or when not to perform CAS before heart surgery. The authors are not vascular surgeons. They opined that "CAS may be even superior to CEA in the context of long-term freedom of death, ipsilateral stroke and myocardial infarction" and "CAS may become the preferred method of obstructive carotid disease treatment in the future." There is abundant literature to the contrary. The reader needs to be aware that the authors excluded unsuccessful CAS procedures and carotid lesions considered high risk for CAS, such as severe calcifications and tortuosity, from analysis. Indeed, <75% of patients who underwent CAS went on to have heart surgery. Although the article provides long-term analysis of death, stroke, and MI after staged CAS and heart surgery, it does not help the clinician decide when to perform CAS (or carotid endarterectomy) before heart surgery.
It is safe to leave the endovascular suite with a type I endoleak after endovascular aneurysm repair Key findings: Of 24 patients who had a proximal type IA endoleak on final intraoperative arteriography, 22 (92%) had spontaneous resolution without intervention during a median 2.5 years of follow-up. One of the other two patients required intervention and the other endoleak did not resolve spontaneously after 4 and 6 years, respectively.
Conclusion: A conservative approach may be used in the management of patients with proximal type IA endoleak on completion arteriography after the maximum proximal seal has been achieved intraoperatively.
Commentary: Not all type I endoleaks are created equal. Although there have been reports of spontaneous resolution of type I endoleaks present at the conclusion of endovascular aneurysm repair (EVAR), more than likely they were small leaks. One reason for spontaneous resolution of any endoleak is reversal of anticoagulation. Interventionalists take a chance if they choose to observe type IA endoleaks and not intervene because the aneurysmal sac may be under the same pressure as before the endograft was placed. I admit there may be instances when the interventionist has done everything reasonable to close a type IA endoleak at the conclusion of EVAR, fenestrated EVAR, or chimney EVAR and (reluctantly) decides to observe the patient to see whether the endoleak resolves but keeps the possibility open of reintervention (including open conversion). Although the authors pointed out that some type I endoleaks can be observed and intervention may not be required, most vascular surgeons would be uncomfortable in taking this approach for the majority of type IA endoleaks. We do not want to be teaching our fellows that it is generally acceptable to leave the operating room with a type I endoleak.
Compared with carotid endarterectomy, the risks of carotid artery stenting are higher the day of the procedure and not during follow-up Key findings: Compared with carotid endarterectomy (CEA; 2271 patients), symptomatic patients treated with carotid artery stenting (CAS; 2236) had higher stroke or death rates (4.7% vs 1.9%) the day of the procedure but not during the following 30 days (2.5% vs 2.0%). Age increased the risk of events both the day of the procedure and during follow-up for CAS.
Conclusion: The increased procedural stroke or death risk associated with CAS compared with CEA in symptomatic patients is caused by an excess of events occurring the day of the procedure. Procedural safety of CAS needs to be enhanced by technical improvements and increased skill of the operator. Higher age increased the risk for both immediate and delayed events in CAS.
Commentary: Compared with CEA, this review showed that CAS is associated with higher risk of stroke or death within 30 days of the procedure in recently symptomatic carotid stenosis. The authors confirmed that most adverse events occurred the day of the procedure and not during follow-up. It has been well established that increasing age is associated with increased risk of CAS because of artery elongation and angulation resulting in more complex anatomy of the supra-aortic arteries and increased calcification of these arteries. Delayed strokes after CAS in the elderly could be due to more unstable atheromatous lesions than in younger patients. Interestingly, the authors found that two-thirds (110/169) of all procedural stroke or death outcomes in patients receiving CAS and about half (42/88) of
